• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对56例住院患者进行为期十年(2003 - 2013年)的回顾性研究,以稳定升高的苯丙氨酸水平。

Ten-year retrospective review (2003-2013) of 56 inpatient admissions to stabilize elevated phenylalanine levels.

作者信息

Clark Anne, Merrigan Christine, Crushell Ellen, Hughes Joanne, Knerr Ina, Monavari Ardeshir A, Treacy Eileen, Coughlan Aoife

机构信息

National Centre for Inherited Metabolic Disorders Temple Street Children's University Hospital Dublin Ireland.

Department of Research Temple Street Children's University Hospital Dublin Ireland.

出版信息

JIMD Rep. 2019 Mar 14;46(1):70-74. doi: 10.1002/jmd2.12019. eCollection 2019 Mar.

DOI:10.1002/jmd2.12019
PMID:31240157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6498819/
Abstract

Phenylketonuria (PKU) is an inherited metabolic disorder affecting phenylalanine metabolism. The Irish incidence is 1:4500. Currently, there are 500 patients under the care of the National Centre for Inherited Metabolic Disorders in Temple Street Children's University Hospital. Current practice is to admit PKU patients with phenylalanine (phe) levels that are consistently out of range despite an intensive multidisciplinary team input on an outpatient basis. The aim of this study was to evaluate changes in phe levels pre, during, and post admissions and to examine if there was a sustained impact post discharge. Fifty-six patients were admitted between January 2003 and December 2013. Patients were all <18 years of age. Greater than 70% (n = 39) of the reasons for admission were due to multiple issues. Average admission time was 5 days. There was a significant decrease in median phe levels from prior to the admission to during the admission. However, there was a significant increase in median phe levels from during the admission (505 μmol/L) to both the 1-6 months' and 7-12 months' time points (618 and 651 μmol/L, respectively). The results highlight that while inpatient admissions can stabilize levels within the acute setting, this is not sustained long term. The ward environment does not accurately replicate home circumstances. This study highlighted that the reasons for admission are most often multifactorial, which is less likely to be resolved during a brief admission period.

摘要

苯丙酮尿症(PKU)是一种影响苯丙氨酸代谢的遗传性代谢紊乱疾病。爱尔兰的发病率为1:4500。目前,有500名患者在坦普尔街儿童医院大学医院的国家遗传性代谢紊乱中心接受治疗。目前的做法是,对于尽管门诊有强化多学科团队干预但苯丙氨酸(phe)水平仍持续超出范围的PKU患者,予以收治入院。本研究的目的是评估入院前、入院期间和入院后phe水平的变化,并检查出院后是否有持续影响。2003年1月至2013年12月期间,共有56名患者入院。患者均未满18岁。超过70%(n = 39)的入院原因是多种问题。平均住院时间为5天。入院前至入院期间,phe水平中位数显著下降。然而,入院期间(505μmol/L)至1 - 6个月和7 - 12个月时间点(分别为618和651μmol/L),phe水平中位数显著升高。结果表明,虽然住院可以在急性期稳定水平,但这种稳定并非长期持续。病房环境无法准确模拟家庭环境。本研究强调,入院原因通常是多因素的,在短暂的住院期间不太可能得到解决。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/6498819/3216a31b3372/JMD2-46-70-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/6498819/3216a31b3372/JMD2-46-70-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/6498819/3216a31b3372/JMD2-46-70-g001.jpg

相似文献

1
Ten-year retrospective review (2003-2013) of 56 inpatient admissions to stabilize elevated phenylalanine levels.对56例住院患者进行为期十年(2003 - 2013年)的回顾性研究,以稳定升高的苯丙氨酸水平。
JIMD Rep. 2019 Mar 14;46(1):70-74. doi: 10.1002/jmd2.12019. eCollection 2019 Mar.
2
Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.葡萄牙代谢中心对苯丙酮尿症患者的代谢控制:三种不同建议的比较。
Nutrients. 2021 Sep 6;13(9):3118. doi: 10.3390/nu13093118.
3
[The maternal phenylketonuria syndrom--still current problem].[母体苯丙酮尿症综合征——仍然是当前的问题]
Przegl Lek. 2009;66(1-2):4-10.
4
5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics.5 年回顾性分析在两家专业诊所治疗的苯丙酮尿症(PKU)和高苯丙氨酸血症患者。
Mol Genet Metab. 2020 Mar;129(3):177-185. doi: 10.1016/j.ymgme.2019.12.007. Epub 2019 Dec 10.
5
Mental health diagnoses in adults with phenylketonuria: a retrospective systematic audit in a large UK single centre.成人苯丙酮尿症患者的精神健康诊断:英国大型单中心回顾性系统审计。
Orphanet J Rare Dis. 2021 Dec 20;16(1):520. doi: 10.1186/s13023-021-02138-z.
6
Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.评估聚乙二醇化苯丙氨酸解氨酶治疗对苯丙酮尿症成人患者饮食的影响:3期临床试验数据分析
Mol Genet Metab. 2024 Mar;141(3):108122. doi: 10.1016/j.ymgme.2023.108122. Epub 2023 Dec 24.
7
Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.聚乙二醇化苯丙氨酸解氨酶在日本苯丙酮尿症成年患者中的两年中期安全性和有效性
Mol Genet Metab. 2023 Nov;140(3):107697. doi: 10.1016/j.ymgme.2023.107697. Epub 2023 Sep 9.
8
The impact of phenylalanine levels during pregnancy on birth weight and later development in children born to women with phenylketonuria.孕妇苯丙氨酸水平对苯丙酮尿症妇女所生孩子出生体重和后期发育的影响。
J Inherit Metab Dis. 2023 Jul;46(4):586-594. doi: 10.1002/jimd.12600. Epub 2023 Mar 6.
9
Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.苯丙氨酸对成年苯丙酮尿症患者认知、大脑和神经代谢参数的影响(PICO 研究):一项随机、安慰剂对照、交叉、非劣效性试验。
Trials. 2020 Feb 13;21(1):178. doi: 10.1186/s13063-019-4022-z.
10
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).培加酶用于治疗苯丙酮尿症:长期 3 期临床试验项目(PRISM)的结果。
Mol Genet Metab. 2018 May;124(1):27-38. doi: 10.1016/j.ymgme.2018.03.006. Epub 2018 Mar 31.

引用本文的文献

1
A Retrospective Chart Review and Infant Feeding Survey in the Irish Phenylketonuria (PKU) Population (2016-2020).爱尔兰苯丙酮尿症(PKU)人群的回顾性图表审查和婴儿喂养调查(2016-2020 年)。
Nutrients. 2023 Jul 29;15(15):3380. doi: 10.3390/nu15153380.
2
Phenylketonuria in the Latvian population: Molecular basis, phenylalanine levels, and patient compliance.拉脱维亚人群中的苯丙酮尿症:分子基础、苯丙氨酸水平及患者依从性
Mol Genet Metab Rep. 2020 Oct 20;25:100671. doi: 10.1016/j.ymgmr.2020.100671. eCollection 2020 Dec.

本文引用的文献

1
Phenylketonuria patients' and their parents' knowledge and attitudes to the daily diet - multi-centre study.苯丙酮尿症患者及其父母对日常饮食的认知与态度——多中心研究
Nutr Metab (Lond). 2017 Aug 17;14:57. doi: 10.1186/s12986-017-0207-1. eCollection 2017.
2
Treatment adherence during childhood in individuals with phenylketonuria: Early signs of treatment discontinuation.苯丙酮尿症患者儿童期的治疗依从性:治疗中断的早期迹象。
Mol Genet Metab Rep. 2017 Apr 28;11:54-58. doi: 10.1016/j.ymgmr.2017.04.006. eCollection 2017 Jun.
3
Adherence to clinic recommendations among patients with phenylketonuria in the United States.
美国苯丙酮尿症患者对临床建议的依从性。
Mol Genet Metab. 2017 Mar;120(3):190-197. doi: 10.1016/j.ymgme.2017.01.001. Epub 2017 Jan 6.
4
Key European guidelines for the diagnosis and management of patients with phenylketonuria.《欧洲苯丙酮尿症患者诊断和管理指南要点》
Lancet Diabetes Endocrinol. 2017 Sep;5(9):743-756. doi: 10.1016/S2213-8587(16)30320-5. Epub 2017 Jan 10.
5
Phenylketonuria patients' and their parents' acceptance of the disease: multi-centre study.苯丙酮尿症患者及其父母对该疾病的接受程度:多中心研究。
Qual Life Res. 2016 Nov;25(11):2967-2975. doi: 10.1007/s11136-016-1326-2. Epub 2016 May 31.
6
Phenylketonuria (PKU): A problem solved?苯丙酮尿症(PKU):问题解决了吗?
Mol Genet Metab Rep. 2015 Dec 29;6:8-12. doi: 10.1016/j.ymgmr.2015.12.004. eCollection 2016 Mar.
7
Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries.评估苯丙酮尿症及其治疗对来自七个欧洲国家的患者及其父母生活质量的影响。
Orphanet J Rare Dis. 2015 Jun 18;10:80. doi: 10.1186/s13023-015-0294-x.
8
Dietary interventions for phenylketonuria.苯丙酮尿症的饮食干预措施。
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD001304. doi: 10.1002/14651858.CD001304.pub2.
9
Living with phenylketonuria: perspectives of patients and their families.苯丙酮尿症患者的生活:患者及其家庭的观点。
J Inherit Metab Dis. 2005;28(5):639-49. doi: 10.1007/s10545-005-4478-8.
10
How practical are recommendations for dietary control in phenylketonuria?苯丙酮尿症饮食控制建议的实用性如何?
Lancet. 2002 Jul 6;360(9326):55-7. doi: 10.1016/s0140-6736(02)09334-0.